The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I study of the anti-HGF monoclonal antibody (mAb), ficlatuzumab, and cetuximab in cetuximab-resistant, recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
 
Julie E. Bauman
Consulting or Advisory Role - AstraZeneca/MedImmune; Incyte; Kolltan Pharmaceuticals; Merck; Merck Serono
Research Funding - AVEO; Bristol-Myers Squibb; Genentech; Lilly; Merck; VentiRx
 
Umamaheswar Duvvuri
Research Funding - Kolltan Pharmaceuticals
 
Robert L. Ferris
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb; Lilly; Merck; Pfizer
Research Funding - AstraZeneca/MedImmune; Bristol-Myers Squibb; Merck; VentiRx
 
James Ohr
No Relationships to Disclose
 
William E. Gooding
No Relationships to Disclose
 
Seungwon Kim
No Relationships to Disclose
 
Jonas Talmadge Johnson
No Relationships to Disclose
 
Jennifer R. Grandis
No Relationships to Disclose
 
Laura P. Stabile
No Relationships to Disclose